PharmaSGP Holding SE

FSX:PSG.DE

21.2 (EUR) • At close September 18, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) EUR.

2024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q1
Revenue 30.20525.42425.96625.69824.01121.87821.95221.42620.56819.17919.73414.08112.3514.6914.74717.07116.73816.85214.17116.59614.955
Cost of Revenue 6.9186.8412.3492.3752.2752.1572.172.2922.4132.5221.6421.2391.0852.0381.4111.5451.2121.4831.3491.4321.604
Gross Profit 23.28718.58323.61723.32321.73619.72119.78219.13418.15516.65718.09212.84211.26512.65213.33615.52615.52615.36912.82215.16413.351
Gross Profit Ratio 0.7710.7310.910.9080.9050.9010.9010.8930.8830.8690.9170.9120.9120.8610.9040.9090.9280.9120.9050.9140.893
Reseach & Development Expenses 000000000000000000000
General & Administrative Expenses 2.6961.791000-26.7481.4251.551.401-21.431-3.068-6.04501.039-1.0511.03900.305-0.5550.570.613
Selling & Marketing Expenses 14.39.81910.81411.42811.3237.3788.6779.12410.43130.84313.35813.358031.64615.93615.936027.82415.57.97.6
SG&A 16.99611.6110.81411.42811.3210.6310.10210.67411.8329.41210.297.3138.23932.68514.88516.9750.64428.12914.9458.478.213
Other Expenses 0.0340.0460.0530.0440.0290.2110.0650.0680.0420.0450.0770.0360.03600000000
Operating Expenses 16.96211.56416.62917.26517.03414.99313.83414.76715.51512.4912.3578.8219.69610.6329.9299.19211.2135.1797.5759.8789.591
Operating Income 6.3257.0197.8956.2654.9774.8555.9484.3672.643.5245.7354.0211.5690.1664.535.2144.3148.0265.2485.2863.76
Operating Income Ratio 0.2090.2760.3040.2440.2070.2220.2710.2040.1280.1840.2910.2860.1270.0110.3070.3050.2580.4760.370.3190.251
Total Other Income Expenses Net -0.243-0.702-1.5-0.942-1.119-0.512-0.696-0.399-0.4-0.314-0.303-0.011-0.0150.024-0.028-0.049-0.022-0.063-0.0090.0150
Income Before Tax 6.0826.3176.3955.3233.8584.3435.2523.9682.243.215.4324.011.5540.194.5025.1654.2927.9635.2395.3013.76
Income Before Tax Ratio 0.2010.2480.2460.2070.1610.1990.2390.1850.1090.1670.2750.2850.1260.0130.3050.3030.2560.4730.370.3190.251
Income Tax Expense 1.5231.5681.6091.3061.01311.3060.9840.5590.8171.3360.9870.3760.0781.081.2961.0552.1231.2581.2750.901
Net Income 4.5594.7494.7864.0172.8453.3433.9462.9841.6812.3934.0963.0231.1780.1123.4223.8693.2375.843.9814.0262.859
Net Income Ratio 0.1510.1870.1840.1560.1180.1530.180.1390.0820.1250.2080.2150.0950.0080.2320.2270.1930.3470.2810.2430.191
EPS 0.380.40.40.340.240.280.330.250.140.20.340.250.10.0090.290.320.270.480.340.330.237
EPS Diluted 0.380.40.40.340.240.280.330.250.140.20.340.250.10.0090.290.320.270.480.340.330.237
EBITDA 8.6599.38110.2368.6227.2887.2198.2676.6684.9065.8896.6064.1941.7330.3084.6585.3244.428.1325.3455.4473.793
EBITDA Ratio 0.2870.3690.3940.3360.3040.330.3770.3110.2390.3070.3350.2980.140.0210.3160.3120.2640.4830.3770.3280.254